Compare · BSX vs LMNX
BSX vs LMNX
Side-by-side comparison of Boston Scientific Corporation (BSX) and Luminex Corporation (LMNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and LMNX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $92.25B.
- Over the past year, BSX is down 39.2% and LMNX is up 13.3% - LMNX leads by 52.6 points.
- BSX has hit the wire 3 times in the past 4 weeks while LMNX has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for LMNX).
- Company
- Boston Scientific Corporation
- Luminex Corporation
- Price
- $62.06-5.52%
- $19.04-1.45%
- Market cap
- $92.25B
- -
- 1M return
- -11.05%
- -10.23%
- 1Y return
- -39.23%
- +13.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest LMNX
- SEC Form 15-12G filed by Luminex Corporation
- SEC Form 4: Eck Stephen L. returned $1,408,701 worth of Common Stock to the company (38,073 units at $37.00) , closing all direct ownership in the company (for withholding tax)
- SEC Form 4: ERICKSON THOMAS W returned $6,932,542 worth of Common Stock to the company (187,366 units at $37.00) , closing all direct ownership in the company to cover taxes
- SEC Form 4: KEVER JIM D returned $8,517,363 worth of Common Stock to the company (230,199 units at $37.00) , closing all direct ownership in the company to satisfy withholding obligation
- SEC Form 4: Lewis Dijuana K returned $257,335 worth of Common Stock to the company (6,955 units at $37.00) , closing all direct ownership in the company
- SEC Form 4: MCNAMARA KEVIN M returned $3,713,616 worth of Common Stock to the company (100,368 units at $37.00) , closing all direct ownership in the company to cover withholding tax
- SEC Form 4: OGUNRO EDWARD A returned $2,253,041 worth of Common Stock to the company (60,893 units at $37.00) , closing all direct ownership in the company to cover taxes
- SEC Form 4: SAMET KENNETH A returned $733,229 worth of Common Stock to the company (19,817 units at $37.00) , closing all direct ownership in the company (withholding tax)
- SEC Form 4: Rew Richard W. II returned $1,760,312 worth of Common Stock to the company (47,576 units at $37.00) , closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: SHAMIR NACHUM returned $8,923,290 worth of Common Stock to the company (241,170 units at $37.00) , closing all direct ownership in the company to cover taxes